

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT6629150

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
CARSGEN THERAPEUTICS LIMITED	03/24/2021
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	CAFA THERAPEUTICS LIMITED
<b>Street Address:</b>	2/3 EXCHANGE PLACE, IFSC
<b>City:</b>	DUBLIN
<b>State/Country:</b>	IRELAND
<b>Postal Code:</b>	D01 AE27
<b>PROPERTY NUMBERS Total: 4</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	14889778
Application Number:	16448053
Application Number:	15326974
Application Number:	15310495
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(650)493-6811
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	650 493-9300
<b>Email:</b>	patentdocket@wsgr.com,klopez@wsgr.com
<b>Correspondent Name:</b>	WILSON SONSINI GOODRICH & ROSATI
<b>Address Line 1:</b>	650 PAGE MILL ROAD
<b>Address Line 4:</b>	PALO ALTO, CALIFORNIA 94304
<b>ATTORNEY DOCKET NUMBER:</b>	60616-70*
<b>NAME OF SUBMITTER:</b>	KATHERINE LOPEZ
<b>SIGNATURE:</b>	/k/
<b>DATE SIGNED:</b>	03/30/2021
<b>Total Attachments: 3</b>	
source=Cafa 60616-700 CARsgen to Cafa Therapeutics Corporate to Corporate Assignment of Entire Interest (Signed)#page1.tif	
source=Cafa 60616-700 CARsgen to Cafa Therapeutics Corporate to Corporate Assignment of Entire Interest	

(Signed)#page2.tif

source=Cafa 60616-700 CARsgen to Cafa Therapeutics Corporate to Corporate Assignment of Entire Interest

(Signed)#page3.tif

**CARsgen Therapeutics Limited**, a corporation incorporated under the laws of China, having a place of business at 4F Building 3, 466 Yindu Road, Xuhui District, Shanghai, China, (the "Assignor"), desires to assign the entire right, title and interest in and to the Inventions and Assigned Patents (each, as defined below) to **Cafa Therapeutics Limited**, a corporation incorporated under the laws of Ireland, having a place of business at 2/3 Exchange Place, IFSC, Dublin, Ireland D01 AE27, (the "Assignee"), and Assignee desires to acquire such right, title and interest, all in the terms and conditions set forth in this Patent Assignment.

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Assignor to have been received in full from said Assignee:

1. Said Assignor has obtained the entire right, title and interest in and to certain new and useful inventions and improvements disclosed in the following patent(s) and patent application(s):

(See Attached Schedule A)

(the "Listed Patent(s)"). As used herein: "Assigned Patents" means (a) the Listed Patent(s), (b) all Patents that share priority with or claim priority to or from the Listed Patent(s), including each and every Patent that is a divisional, substitution, continuation, continuation-in-part, non-provisional, or national phase application of any of the Listed Patent(s), (c) all Patents applied for on an invention disclosed within the Patents included in foregoing subclauses (a)-(b), (d) each and every Patent granting, issuing or reissuing from any of the foregoing under subclauses (a)-(c), (e) each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing under subclauses (a)-(d), and (f) each and every Patent filed outside the United States and corresponding to any of the foregoing under subclauses (a)-(e). "Patents" means (i) patents, certifications of inventions, inventor's certificates and other forms of protection granted on any invention in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise, and (ii) applications therefor (whether provisional, converted provisional, utility, design, plant, utility model, non-provisional or otherwise).

2. Said Assignor does hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to the Assigned Patents, including the right to claim priority to and from said Assigned Patents; (b) in and to the inventions disclosed in the Assigned Patents, and in and to all embodiments of the inventions (the "Inventions") and (c) in and to all claims for past, present and future infringement of the Assigned Patents, including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Assigned Patents.

3. Said Assignor hereby covenants and agrees to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Assignor shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for filing, prosecuting or maintaining any of the Assigned Patents; (c) for filing, prosecuting or maintaining applications for reissuance of any said Assigned Patents; (d) for interference or other priority proceedings involving said Assigned Patents or Inventions; and (e) for legal proceedings involving said Inventions or Assigned Patents, including without limitation reissues and reexaminations, IPRs, opposition and other post-grant proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that reasonable expenses incurred by said Assignor in providing such cooperation shall be paid for by said Assignee.

4. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, and assigns, and shall be binding upon said Assignor and its assigns.

5. Said Assignor hereby warrants, represents and covenants that Assignor has not entered and will not enter into any assignment, contract, or understanding in conflict herewith.



6. Said Assignor hereby requests that any Assigned Patents issuing or granting in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued or granted in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors and assigns.

///

///

///

116 12007  
14007  
14007

<b>CORPORATE TO CORPORATE PATENT ASSIGNMENT</b>	Docket Number 60616-700
<p>///</p> <p>7. This instrument will be interpreted and construed in accordance with the laws of the State of California, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.</p>	
<p>IN WITNESS WHEREOF, said Assignor has executed and delivered this instrument to said Assignee as of the date written below:</p>	
<p>AGREED TO BY ASSIGNOR: <b>CARsgen Therapeutics Limited</b></p> <p>Date: <u>March 24, 2021</u> Signature:  Name: Zonghai Li Title: Chief Executive Officer</p>	
<p>RECEIVED AND AGREED TO BY ASSIGNEE: <b>CAFA THERAPEUTICS LIMITED</b></p> <p>Date: <u>March 24, 2021</u> Signature:  Name: Huamiao Wang Title: Company Secretary</p>	

Schedule A

Title	Appl No# (Patent Number)	Filing Date (Issue Date)	Status
CHIMERIC ANTIGEN RECEPTORS TARGETING GPC3 AND USE THEREOF	14/889,778 (10/731,127)	Mar. 1, 2016 (Aug. 4, 2020)	Issued
IMMUNOLOGIC EFFECTOR CELL OF TARGETED CLD18A2, AND PREPARATION METHOD AND USE THEREOF	16/448,053	June 21, 2019	Pending
IMMUNOLOGIC EFFECTOR CELL OF TARGETED CLD18A2, AND PREPARATION METHOD AND USE THEREOF	15/326,974 (10,377,822)	Jan. 17, 2017 (Aug. 13, 2019)	Issued
NUCLEIC ACIDS ENCODING CHIMERIC ANTIGEN RECEPTOR PROTEINS WHICH BIND EPIDERMAL GROWTH FACTOR RECEPTOR AND T LYMPHOCYTE EXPRESSING THE PROTEIN	15/310,495 (10,604,740)	Nov. 11, 2016 (Mar. 31, 2020)	Issued